ayurvedic aetiopathogenesis of amavata with therapeutic effect of pathyadi churna

Not yet recruiting

• Conditions: Rheumatoid arthritis with rheumatoid factor without organ or systems involvement. Ayurveda Condition: AMAVATAH,

• Registration Number: CTRI/2023/05/053041
• Lead Sponsor: Dr Ashu

Brief Summary

**Introduction:** The study is an open label, single arm, prospectiveclinical trial in Amavata (Rheumatoid Arthritis) (n=60)selected using the convenience (non-random) sampling technique with pre andpost design          conducted in tertiary Ayurveda Hospital attached to VYDS AyurvedaMedical College located in district Bulandshahar India, irrespective of caste, sex, occupation andsocio-economic status etc.

**Diagnostic Criteria :**Angamarda, Aruchi, Trishna, Alasya, Gaurava, Jwara, Apaka, Sandhi Shotha, and 2010 ACR-EULAR 114 classificationcriteria for Rheumatoid Arthritis with grading score.

LABORATORYINVESTIGATION: ESR, (Hb gm %),Urine Analysis, Serum uric acid level was estimated to rule out the possibility of other pathological conditions.

**Bio- Markers** :Rheumatoid Factor (RF), C- Reactine Protein (CRP).

**POSOLOGY: Drug- Pathyadi Churna (Bhavaprakash ) 3g BID with Luke warm water For 30 days.**

**FINAL ASSESSMENT OF RESULT: Patients will be assessed before & after the treatment (30 days) for improvement in symptoms on the basis of said scoring pattern & percentage improvement would be calculated.**

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-05-22
• Study Start: 2023-05-31

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Angamardha, Aruchi, Trishna, Alasya, Gaurava, Jwara, Apaka, Sandhi Shotha, and 2010 ACR-EULAR classification criteria for Rheumatoid Arthritis.
• Subjects aged between 20-60 years 3.
• Subjects of either gender 4.
• Subjects willing to participate in the study and ready to sign informed consent form.

Exclusion Criteria

• Subjects with known case of essential hypertension and uncontrolled diabetes mellitus 2.
• Subjects with known case of impaired renal, hepatic and cardiac function 3.
• Subjects with known case of systemic arthritis (gout, tubercular arthritis, systemic lupus erythematosus, psoriatic arthritis) 4.
• Pregnant and Lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A joint involvement (0–5 points)	30 days
1 large joint 0	30 days
2–10 large joints 1	30 days
1–3 small joints 2	30 days
Low positive RF or low positive ACPA 2	30 days
4–10 small joints 3	30 days
10 joints including at least one small joint 5	30 days
B Serology 0–3 points	30 days
Negative RF and negative ACPA 0	30 days
High positive RF or high positive ACPA 3	30 days
C Acute-phase reactants 0–1 point	30 days
Normal CRP and normal ESR 0	30 days
Abnormal CRP or abnormal ESR 1	30 days
D Duration of symptomsed	30 days
6 weeks 0	30 days
≥6 weeks 1	30 days

Secondary Outcome Measures

Name	Time	Method
Ayurvedic Assessment parameter	1 Angamarda

Trial Locations

Locations (1)

Dept. Of Rog Nidan and Vikriti Vigyan Vaidya Yagya Dutt Sharma Ayurved College; 🇮🇳 Bulandshahar, UTTAR PRADESH, India

Dept. Of Rog Nidan and Vikriti Vigyan Vaidya Yagya Dutt Sharma Ayurved College

🇮🇳Bulandshahar, UTTAR PRADESH, India

Dr Ashu

Principal investigator

9318809011

dr.ashu007@yahoo.com